mp.weixin.qq.com·· 10 hours agoPickScore96
SAFFRON Global Phase III: Osimertinib Plus Savolitinib Cuts Risk of Progression or Death 45% in MET-Altered EGFR-Mutant Lung Cancer
In brief
The global Phase III SAFFRON trial showed that osimertinib combined with savolitinib reduced the risk of disease progression or death by 45% versus platinum doublet chemotherapy in MET-altered, EGFR-mutated NSCLC (PFS HR 0.55; 95% CI 0.42-0.72; p<0.001).
Why it matters
SAFFRON quantifies PFS, OS and safety of the combination versus chemotherapy in a randomized Phase III design, enabling comparison of this later-line regimen.
Source: mp.weixin.qq.com · mp.weixin.qq.com